Sarepta Therapeutics Inc (NASDAQ:SRPT) has been upgraded to Market Perform in a report by Leerink Swann today.
- Updated: September 19, 2016
Only yesterday Sarepta Therapeutics Inc (NASDAQ:SRPT) traded 91.30% higher at $51.30. SRPT’s 50-day moving average is $26.16 and its 200-day moving average is $20.47. The last stock close is up 163.13% relative to the two hundred day average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the date range. Trade volume was was up over the average, with 29,541,278 shares of SRPT changing hands over the typical 2,328,380 shares..
Leerink Swann has upgraded Sarepta Therapeutics Inc(NASDAQ:SRPT) to Market Perform in a report released Monday September 19 2016.
Previously on 7/22/2016, Needham reported about Sarepta Therapeutics Inc(NASDAQ:SRPT) upped the target price from $20.00 to $26.00. At the time, this suggested an upside of 0.15%.
Also covering Sarepta Therapeutics Inc’s stock price target, a total of 13 brokerages have issued a ratings update on the company. The 12-month target stock price is $20.77 with three analysts rating the company a strong buy, one analyst rating the stock a buy, five firms rating the stock a hold, four analysts rating the company to underperform, and lastly one firm rating the stock as sell.
With a market capitalization of $0.0, Sarepta Therapeutics Inc has a price-earnings of 0 with a 52 week low of $8.00 and a 52 week high of $56.18.
More About Sarepta Therapeutics Inc (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.